Evidence map›Paper›PMID 40948771›Full record

ArticleFrontiers in immunology2025

Risk factors and a new nomogram for glioblastoma: based on a retrospective study.

Bo Wu, Congying Zheng, Chengliang Mao

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bo WuDepartment of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
Congying ZhengDepartment of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
Chengliang MaoDepartment of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma (GBM) is the most common and aggressive primary malignant tumor of the adult central nervous system. Despite multimodal therapy, its prognosis remains poor, with a median overall survival of 14-16 months. While rare genetic syndromes and prior cranial irradiation have been implicated, definitive environmental or biological risk factors for GBM remain elusive. Methods: In this retrospective study, we analyzed data from 94 patients with pathologically confirmed GBM and 94 matched non-tumor controls treated at Guangdong Academy of Medical Sciences between 2016 and 2023. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors, which were subsequently used to construct a predictive nomogram. Model performance was assessed using concordance index (C-index), receiver operating characteristic (ROC) curves, and calibration plots in both training and validation cohorts. Results: Six independent risk factors were identified: serum chloride (Cl), magnesium (Mg), high-density lipoprotein cholesterol (HDL-C), uric acid (UA), eosinophil count, and basophil count. A novel nomogram incorporating these factors demonstrated strong predictive ability, with a C-index of 0.871. Conclusions: We present a validated, blood-based nomogram for GBM risk prediction with high discriminative power. This model may aid clinicians in early identification and personalized management of high-risk individuals.

Indexed as

Brain NeoplasmsGlioblastomaNomogramsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsROC Curveglioblastomamachine learningnomogramretrospective studyrisk factors

Identifiers

PMID40948771
PMCPMC12426093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.